AstraZeneca Bets Cancer Picks Up Diabetes Slack in New Plan

Updated on
  • New long-term plan reflects confidence in Lynparza, AZD9291
  • Diabetes drugs in U.S. not performing as well as expected

AstraZeneca Plc projected a slowdown in U.S. sales of diabetes treatments, echoing comments by competitors and putting the onus on its cancer drugs to help meet its long-term sales target.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.